Tolerability & Safety of Premarin Vaginal Cream in Indian Postmenopausal Women
NCT00484107
Last updated date
ABOUT THIS STUDY
This post-marketing study will provide local safety and tolerance data on the use of
Premarin® vaginal cream.
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Postmenopause
Sex
Female
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
Adult Trials: 18+ Years
40-65 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details
- Patients in whom Premarin vaginal cream is indicated.
- In the opinion of the investigator, sufficient intelligence and motivation for the patient to continue throughout the study.
- Provide signed informed consent.
Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
- Patients not willing to give informed consent.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
Clinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
PostmenopauseStudy Evaluating Premarin and Bazedoxifene Potential Interaction
NCT00745173
- Austin, Texas
Female
35 Years+
years
MULTIPLE SITES
PostmenopauseTolerability & Safety of Premarin Vaginal Cream in Indian Postmenopausal Women
NCT00484107
Female
40 Years+
years
MULTIPLE SITES
PostmenopauseStudy Evaluating Three Bazedoxifene/Conjugated Estrogens Combination Tablet Formulations Versus BZA Oral Solution
NCT00367536
Female
35 Years+
years
MULTIPLE SITES
PostmenopauseStudy Evaluating Bazedoxifene/CE in Postmenopausal Women
NCT00550433
Female
35 Years+
years
MULTIPLE SITES
Advanced Information
| Descriptive Information | ||||
|---|---|---|---|---|
| Brief Title | Tolerability & Safety of Premarin Vaginal Cream in Indian Postmenopausal Women | |||
| Official Title | A Postmarketing Surveillance Study Evaluating the Tolerability and Safety of PREMARIN VAGINAL CREAM in Indian Postmenopausal Women | |||
| Brief Summary | This post-marketing study will provide local safety and tolerance data on the use of Premarin® vaginal cream. | |||
| Detailed Description | Not Provided | |||
| Study Type | Observational | |||
| Study Design | Not Provided | |||
| Target Follow-Up Duration | Not Provided | |||
| Biospecimen | Not Provided | |||
| Sampling Method | Not Provided | |||
| Study Population | Not Provided | |||
| Condition | Postmenopause | |||
| Intervention | Drug: Conjugated Estrogen Cream (Premarin®) | |||
| Study Groups/Cohorts | Not Provided | |||
| Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
| Recruitment Information | ||||
| Recruitment Status | Completed | |||
| Enrollment | 200 | |||
| Original Enrollment | Same as current | |||
| Actual Study Completion Date | October 2006 | |||
| Primary Completion Date | Not Provided | |||
| Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria:
| |||
| Sex/Gender |
| |||
| Ages | 40 Years to 65 Years (Adult, Older Adult) | |||
| Accepts Healthy Volunteers | No | |||
| Contacts | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries | Not Provided | |||
| Removed Location Countries | ||||
| Administrative Information | ||||
| NCT Number | NCT00484107 | |||
| Other Study ID Numbers | 0713V-101833 | |||
| Has Data Monitoring Committee | Not Provided | |||
| U.S. FDA-regulated Product | Not Provided | |||
| IPD Sharing Statement | Not Provided | |||
| Responsible Party | Not Provided | |||
| Study Sponsor | Wyeth is now a wholly owned subsidiary of Pfizer | |||
| Collaborators | Not Provided | |||
| Investigators |
| |||
| PRS Account | Wyeth is now a wholly owned subsidiary of Pfizer | |||
| Verification Date | December 2007 | |||